CRC HPP

Clinical Research Centre

Hospital Pulau Pinang
Georgetown, Pulau Pinang

WhoWe Are

Established in 2001 and operational since 2003, Clinical Research Centre Hospital Pulau Pinang (CRC HPP) began in a small office with four staff members at the current CTC clinic, relocated to the 1st floor of the ACC Building in 2009, and expanded to the CRC Complex building in 2019 to enhance support for research activities at Hospital Pulau Pinang. The mission of CRC HPP is to improve patient health outcomes through ethical and high-quality clinical research, while its vision is to synthesize evidence within the Malaysian context to inform and update policies. The objectives of CRC HPP are to conduct and support research by providing essential services and facilities, promote a research culture and enhance research capacity through data resources and training, and produce impactful, evidence-based research to advance the healthcare system.

OurTeam

NAME	POSITION	QUALIFICATION	EMAIL
NAME	POSITION	QUALIFICATION	EMAIL
Dr. Yoon Chee Kin	Head, Acute Medicine Physician	MBBChBAO, MMed, MRCP, MRCP (IRE)	dryoonck@moh.gov.my
Ng Ru Shing	Deputy Head, Pharmacist	MPharm	nrshing@moh.gov.my
Dr. Wee Hong Chin	Medical Officer	MD	wee.hongchin@moh.gov.my
Teo Ley Khim	Pharmacist (Admin Manager I)	MPharm	teolk@crc.moh.gov.my
Ch'ng Chin Chin	Pharmacist (Admin Manager II)	BPharm, MPH	chngchinchin@moh.gov.my
Lim Yen Li	Pharmacist	MPharm	limyenli@crc.moh.gov.my
Dr. Sivasangari a/p Subramaniam	Research Officer	PhD	sivasangarisubramaniam@moh.gov.my
Dr. Kelvin Beh Khai Meng	Medical Officer	BM	kelvinbeh@crc.moh.gov.my
Dr. Goh Lay Hoon	Medical Officer	MD	gohlayhoon@moh.gov.my
Dr. Tan Xue Fang	Medical Officer	MBBS	tanxuefang@moh.gov.my
Dr. Cheng Jie Ling	Medical Officer	MBBS	chengjl@moh.gov.my
Zarina bt Che Umar	Sister	Diploma In Nursing	zarinacu@gmail.com
Khadijah bt Majid	Administrative Assistant	Bachelor Degree	khadijah.abdmajid@moh.gov.my

InvestigatorsHighlight

Dr. Yoon Chee Kin

Head of CRC, Acute Medicine Physician, Hospital Pulau Pinang

Email: dryoonck@moh.gov.my

MBBChBAO (IRE), MRCP (UK), MRCP (IRE), MMed (S’PORE), MBA

Areas of interest: Non-communicable diseases, Maternal health, Diabetes

Awards and achievements:

Excellent Service Award, Ministry of Health Malaysia (2007, 2012, 2017, 2022)
Clinical Research Malaysia Award for Top Ministry of Health Study Site - 2022

Dr. Yoon is dedicated to translating the extensive body of research evidence into tangible improvements in community health. His work involves not only applying this knowledge to enhance health outcomes but also shaping the future of clinical practice through the development of guidelines. In addition, Dr. Yoon actively contributes to special interest groups that focus on critical areas such as non-communicable diseases, maternal health, and diabetes. His commitment extends to influencing policy and practice in these fields, aiming to bridge the gap between research and real-world health applications.

Research Highlights

Dr. Yoon has contributed as an author to Clinical Practice Guidelines (CPG) on topics including bronchial asthma in adults, advanced care planning, and urinary tract infections during pregnancy. Additionally, he serves as a reviewer for the Malaysian Clinical Practice Guidelines (CPG) concerning systemic lupus erythematosus, hepatitis B, and rheumatoid arthritis.

Recent Publications

Clinical Practice Guidelines 2023 Management of Systemic Lupus Erythematosus

Clinical Practice Guidelines 2022 Management of Chronic Hepatitis B in Adults

Clinical Practice Guidelines 2019 Management of Rheumatoid Arthritis

Development of a mortality score to assess risk of adverse drug reactions among hospitalized patients with moderate to severe chronic kidney disease

Efficacy of Oral Mixed Tocotrienols in Diabetic Peripheral Neuropathy: A Randomized Clinical Trial

Project Highlights

Investigator Initiated Trial/ Research (IIT/ IIR)
Industry Sponsored Research (ISR)

	MyGenom initiative: Establishing a reference genome for precision medicine in Malaysia
	Ministry of Health (MOH) Biobank, Institute for Medical Research, Ministry of Health
NMRR-23-01702-MJA	Incidence and Characteristics of Acute Kidney Injury among Hospitalized Dengue Patients
NMRR-23-02619-POU	A prospective cohort study on a novel surgical technique Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal diseases in Malaysia.
NMRR-23-02480-SGV	Prevelance Risk Factor and Etiology of onychomycosis in psoriasis patients
NMRR-22-02846-I21	Development and Validation of Usability and Satisfaction of Health Application Questionnaire (USHA)
NMRR-18-2593-43921	Epidemiology, incidence, and clinical outcomes of snake bites treated in Hospital Pulau Pinang
RSCH-23-00281-MGB	Incidence and Characteristics of Acute Kidney Injury among Hospitalized off pump and on pump CABG patients
NMRR	id - 2024study done in 2024

NMRR-21-644-59445	The Malaysian Study on Hemodialysis patients SARS-Cov-2 Vaccination Immune Response: A prospective cohort study
NMRR-23-02321-TFP	Epidemiology and Clinical Characteristics of Pemphigus in a Tertiary Hospital in Penang : A 11-Year Retrospective Study
NMRR-23-00861-1N5	Factors affecting success and failure of urethroplasty surgery in male urethral strictures : Single Surgeon Center Experience
NMRR-24-00148-KX7	Evaluating The Preliminary Outcomes Of Post Thoracic Endovascular Aortic Repair In A Single Center: A Retrospective Descriptive Cross Sectional Study
NMRR-24-00047-HB7	Traumatic Aortic Valve Rupture: A Case Report
NMRR-20-2619-56326	Preoperative Haematocrit and Packed Red Blood Cell (PRBC) Transfusion during Isolated Coronary Artery Bypass Grafting (CABG) at Penang General Hospital
RSCH-23-00280-WFH	Bridging the gap between Evidence Based Practice and Nursing Care: A Prospective Analytical Cross Sectional Study
NMRR-21-02036-YOX	Changes in blood pressure after Pfizer/BioNTech SARS-Cov-2 vaccination
NMRR-15-496-25490	Use of Baclofen in Outpatient Clinic Setting
NMRR-17-3287-36091	Survival of End Stage Renal Failure patients with and without dialysis
NMRR-14-1526-23748	An open-label study of combination of Cinacalcet and active vitamin D analogue in the management of the Severe Secondary hyperthyroidism in Haemodialysis Patients
NMRR-14-1482-23731	A prospective, observational, non-inferior study to assess the effectiveness of a biosimilar epoetin alfa (Binocrit) in maintaining haemoglobin levels in stable ESRF patients on haemodialysis
NMRR-08-789-1944	Audit of CAPD peritonitis in MOH centres in Malaysia
NMRR-16-2183-33284	Prevalence and risk factor of proteinuria in Orang Asli population in Malaysia
NMRR-20-211-52663	A prospective observational study to assess the effectiveness and safety of sofosbuvir plus daclatasvir (SOF-DCV) with or without ribavirin (RBV) in chronically infected HCV patients with end-stage renal failure receiving renal replacement therapy under real-world clinical setting in Malaysia
NMRR-22-00977-CQB	Epidemiology, Clinical Features and Risk Factors for Disease Severity in Children with COVID-19
NMRR-14-950-20443	Effect of sodium rinsing fluid on blood pressure and interdialytic weight change in haemodialysis patients
NMRR-16-2033-32927	A prospective, multicenter, observational study to determine the incidence and outcome of Acute Kidney Injury among hospitalised patients in Malaysia
NMRR-12-1385-11410	Effectiveness of Propranolol in Improving Language Function in Children with Autism Spectrum Disorder
NMRR-20-1844-55868	Development and Validation of Patient Diabetes Knowledge Questionnaire (PDKQ)
NMRR-19-2518-48707	Effects of time restricted feeding on body weight and metabolic syndrome severity in the obese adults. A pilot randomized controlled trial
NMRR-18-1393-42263	Glycaemic control among diabetes patients in pharmacist managed insulin titration
NMRR-19-2066-49960	A Randomize, Double-blind, placebo-controlled study, to assess the efficacy and safety of Tocovid Suprabio 200mg in Non-alcoholic fatty liver (NAFL)
NMRR-23-00735-4MU	IMPACT OF FACIAL ACNE SCARS ON PSYCHOSOCIAL HEALTH
NMRR-24-00984-OZ9	Diffuse Alveolar Haemorrhage and Occlusive Vasculopathy Induced by Hyaluronic Acid Cosmetic Filler Injections for Breast Augmentation. A case report.
NMRR-20-1207-55463	Global Estimation of COVID-19 Infections and Related Deaths among Healthcare Workers
NMRR-19-464-46246	Prevalence and risk factors of osteoporosis in rheumatoid arthritis patients
NMRR-19-3368-51968	The risk of tuberculosis in patients on biologics for rheumatic diseases
NMRR-19-2386-47755	Incidence and Outcomes of In-Hospital Cardiac Arrest (IHCA): A 12-Month Audit in a Malaysian Tertiary Care Hospital
NMRR-18-3761-44848	Aspirin (ASA) Desensitization in Patients With Coronary Artery Disease (CAD)

NMRR-20-2951-57003	A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer (TIGIT)
NMRR-22-02070-23D	A Randomized, Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety, and Dose Response Of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
NMRR-23-01871-OBV	A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthmas (LITHOS)
NMRR-23-00606-M4P	MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
NMRR-24-00102-YRK	A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease
NMRR-24-01815-KDL	Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
NMRR-23-01854-V44	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Treatment With Osimertinib (SAFFRON)

NMRR-16-1077-30703	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT - CONVERSION)
NMRR-16-1514-31819	A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
NMRR-16-2553-33457	A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (Voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis
NMRR-16-2252-33598	A 52-week open-label (sponsor-blind), randomized, active- controlled, parallel-group, multi-center study to evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoietin in subjects with anemia associated with chronic kidney disease who are initiating dialysis
NMRR-17-1753-37068	A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism
NMRR-17-3137-38670	A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis
NMRR-18-3256-44987	A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naive, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
NMRR-19-739-46920	FLOW - Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
NMRR-19-1288-48307	A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
NMRR-19-1491-48537	A Phase II two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy.
NMRR-20-1273-54343	A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
NMRR-21-688-58898	A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination with Platinum+Pemetrexed Chemotherapy in Subjects with First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer
NMRR-18-1266-41897	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease